NasdaqCM:ATOS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-37	-20	-26	3
12/31/2025	N/A	-32	-9	-27	4
12/31/2024	N/A	-27	N/A	-24	4
9/30/2024	N/A	-27	-20	-20	N/A
6/30/2024	N/A	-26	-19	-19	N/A
3/31/2024	N/A	-30	-19	-19	N/A
12/31/2023	N/A	-30	-21	-21	N/A
9/30/2023	N/A	-30	-20	-20	N/A
6/30/2023	N/A	-32	-21	-21	N/A
3/31/2023	N/A	-28	-23	-23	N/A
12/31/2022	N/A	-27	-21	-21	N/A
9/30/2022	N/A	-24	-20	-20	N/A
6/30/2022	N/A	-21	-18	-18	N/A
3/31/2022	N/A	-22	-17	-17	N/A
12/31/2021	N/A	-21	-16	-16	N/A
9/30/2021	N/A	-28	-16	-16	N/A
6/30/2021	N/A	-26	-16	-16	N/A
3/31/2021	N/A	-23	-13	-13	N/A
12/31/2020	N/A	-22	-12	-12	N/A
9/30/2020	N/A	-13	-11	-11	N/A
6/30/2020	N/A	-13	-10	-10	N/A
3/31/2020	N/A	-16	-10	-10	N/A
12/31/2019	N/A	-17	-9	-9	N/A
9/30/2019	N/A	-17	-9	-9	N/A
6/30/2019	N/A	-17	-9	-9	N/A
3/31/2019	N/A	-25	-9	-9	N/A
12/31/2018	N/A	-23	-9	-9	N/A
9/30/2018	N/A	-23	-8	-8	N/A
6/30/2018	N/A	-22	N/A	-8	N/A
3/31/2018	N/A	-11	N/A	-7	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-11	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-6	N/A	-4	N/A
12/31/2016	N/A	-6	N/A	-5	N/A
9/30/2016	0	-6	N/A	-8	N/A
6/30/2016	0	-10	N/A	-12	N/A
3/31/2016	0	-12	N/A	-14	N/A
12/31/2015	0	-13	N/A	-14	N/A
9/30/2015	0	-13	N/A	-13	N/A
6/30/2015	0	-13	N/A	-12	N/A
3/31/2015	0	-13	N/A	-11	N/A
12/31/2014	0	-12	N/A	-11	N/A
9/30/2014	0	-12	N/A	-10	N/A
6/30/2014	0	-12	N/A	-10	N/A
3/31/2014	0	-11	N/A	-10	N/A
12/31/2013	1	-11	N/A	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ATOS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATOS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ATOS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ATOS来年は収益がないと予測されています。

高い収益成長: ATOS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ATOSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/26 07:44
終値	2024/12/26 00:00
収益	2024/09/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Atossa Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。9

アナリスト	機関
Edward Woo	Ascendiant Capital Markets LLC
Louise Chen	Cantor Fitzgerald & Co.
Pooya Hemami	Edison Investment Research

Atossa Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 7.7% to US$5.83

Forecast to breakeven in 2026

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2026

Price target decreased by 7.5% to US$4.63

Recent updates

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z-Endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Price target decreased to US$6.38